ClinicalTrials.gg
Active, not recruitingNCT07020416Updated Nov 3, 2026

AutoSTEA for Adults With Functional Dyspepsia

A Phase 1 interventional study of Transcutaneous electrical acustimulation in automatic synchronization with breathing in Functional Dyspepsia, sponsored by MetroHealth Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by MetroHealth Medical Center · Phase 1, Interventional, and Device feasibility

How we know

Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Dyspepsia with a site in United States — 14 open to participants now, 18 under way, 1 of them phase 3. Dyspepsia · United States.

Planned enrollment
51st of 67
20 · median 50
Started
2025
with 3 others
Phase 1
6 of 77
none open now
Primary completion
2030-01
later than 15 of 17 live
Registered
73rd of 77
by date

Among the 77 studies in Dyspepsia with a site in United States, this one is the 51st largest by planned enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2025, is one of 6 in phase 1, reaches primary completion later than 15 of the 17 other live ones, and was the 73rd registered.

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

14 of the 77 studies in Dyspepsia with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Dyspepsia with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to assess how effective the AutoSTEA device is in treating functional dyspepsia (upper abdominal discomfort) in adults. It will also assess the safety and usability of the device. The main questions it aims to answer are:

  • Does the AutoSTEA device ease dyspepsia symptoms?
  • Is the AutoSTEA device safe and feasible for patients to use at their home?

Participants will:

  • Use the device for half an hour every day for two weeks
  • Have a phone check-in halfway through the trial
  • Answer the daily and weekly questionnaires which consist of questions - regarding symptoms, device usability, and adverse events experienced.
03

Conditions studied

  • Functional Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 and older
  • Must meet Rome IV criteria for functional dyspepsia

Exclusion criteria

Exclusion Criteria:

  • Patients with dyspepsia symptoms that have been fully resolved by antisecretory, antidepressant, or prokinetic therapy
  • History of active NSAID use, unhealed esophagitis, unhealed ulcer disease, or other GI diseases that can explain their dyspepsia symptoms.
  • History of upper GI surgeries and upper GI cancers, uncontrolled diabetes (type 1 and 2), severe psychiatric conditions, uncontrolled medical disorders, total knee replacement surgery, or above-the-knee amputation.
  • Patients with H. pylori infection without confirmed eradication will also be excluded.
05

Study design

Phase
Phase 1
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Adult patients with functional dyspepsia

    The treatment this arm will be administered is the AutoSTEA treatment, which consists of a band-like device that wraps around the rib cage. This device is connected to a microstimulator which is then connected to TENS pads. The band allows for the electrical impulses given to be synchronized with one's breathing.

    Device: Transcutaneous electrical acustimulation in automatic synchronization with breathing

Interventions

  • DeviceTranscutaneous electrical acustimulation in automatic synchronization with breathing

    This intervention will be carried out via the AutoSTEA device.

06

What researchers measure

Primary outcomes

  1. Determine the device safety when self-administered at home by patients

    Assess any adverse effects the device may have when used by patients in their home. This will be done using the device safety questionnaire. The safety questionnaire is to filled out weekly, with any adverse event that is experienced being reported. These adverse events (if applicable) will be rated in severity on a 0-5 scale, with 0 being the least severe and 5 being the most severe.

    Time frame: From enrollment to the end of treatment in two weeks

  2. Evaluate device usability

    Assess how easy the device is for patients to use in their home. This will be done using the usability questionnaire. This questionnaire will be filled out daily and the user will rate on a 0-5 scale (with 0 being the worst and 5 being the best) how easy and comfortable the device was for them.

    Time frame: From enrollment to the end of treatment in two weeks

  3. Assess symptom responses to treatment

    Assess how well a patient's dyspepsia symptoms respond to the treatment. This will be done via two questionnaires. One will be filled out weekly, where patients describe how much their dyspepsia symptoms have affected their daily lives. The scale for this will be 0-4, with 0 being no effect on their daily life and 5 being extreme effect on their daily lives. The second questionnaire will be filled out daily, and it describes the physical dyspepsia symptoms experienced by the patient in the last 24 hours. It is done on a scale from 0-10, with 0 meaning they have not experienced a symptom at all, and 10 being they have severely experienced a symptom.

    Time frame: From enrollment to the end of treatment in two weeks

Secondary outcomes

  1. Assess a diverse participant pool, especially overweight/obese female patients

    Assess the response that patients have with a focus on those who are overweight/obese and female. This will be analyzed via the two dyspepsia symptom questionnaires that are mentioned in outcome 3.

    Time frame: From enrollment to the end of treatment in two weeks

  2. Assess patient's compliance to AutoSTEA treatment

    Assess if patients followed through with the required usage of the device and treatment. This will be done via their own self-reporting to study staff of if they missed any treatment days.

    Time frame: From enrollment to the end of treatment in two weeks

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This data is preliminary data which we will use for IP protection and pattern application. We will keep the data confidential prior to future publication.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2025 (actual). Primary completion is estimated for Jan 2030, 59 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Apr 2026 → Jan 2030 and completion Feb 2027 → Jul 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
Jun 13, 2025
StartActual
Feb 26, 2025
Primary completionEst.
Jan 2030was Apr 2026
CompletionEst.
Jul 2030was Feb 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Jan 2030
Nov 3, 2026
Study completion
Feb 2027→Jul 2030
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Apr 2026→Jan 2030
    Study completion Feb 2027→Jul 2030
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07020416
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Feb 26, 2025
Primary completion
Jan 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Michael Kurin, MD
principal investigator · MetroHealth Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion